Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 352 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line... June 25, 2025 ASCO 2023 roundup: Blood tests, drugs and exercise June 12, 2023 Telephone-Based Rehab Program Helps People with Advanced Cancer Maintain Independence April 29, 2019 Breakfast Ideas August 21, 2020 Load more HOT NEWS Researchers Create Modified Antibodies to Target RAS and p53 in Cancer ESMO Clinical Practice Guideline Express Update on the adoption of physical... Death Rates from Lung Cancer will Fall Overall in the EU... Singer Surprises 6-Year-Old Fan Who Beat Cancer With Trip To Disney
